Samuel Broder

Samuel Broder 1986

Samuel Broder (born February 24, 1945 ) is an American oncologist and AIDS researcher.

Broder studied at the University of Michigan with a bachelor's degree in 1966 and a doctorate in medicine (MD) in 1970. From 1972 he was at the National Cancer Institute (NCI), initially in the metabolism department. In 1973 he received his medical license in internal medicine and in 1977 in oncology. In 1981 he became the assistant director of the Clinical Oncology Program and from 1989 to 1994 he was the director of the NCI. During his time the clinical tests of paclitaxel took place as a chemotherapeutic agent against cancer. Bristol-Myers Squibb was selected as the company partner for the market launch , which in 1989 led to controversy.

He was involved in the development of the first effective anti- AIDS drugs in the 1980s , zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC). At the NCI, AZT had already been developed as a possible cancer therapeutic and was tested on AIDS patients after the outbreak of the epidemic. At the time, the NCI was the only institute of the National Institutes of Health that could independently develop drugs and stepped in in difficult areas in which the pharmaceutical industry did not want or was unable to get involved.

In 1995 he became Vice President of Research and Chief Scientific Officer of Ivax Corporation in Florida. In 1998, he moved to Celera Genomics in Rockville, Maryland , where he was Chief Medical Officer and Executive Vice President. He then served as Executive Vice President and Head of Healthcare at Intrexon, which he retired in 2016.

He is a member of the Institute of Medicine . In 1992 he received the Léopold Griffuel Prize and the Arthur S. Flemming Award from the US government.

Web links

• Samuel Broder to the NIH

Individual evidence

1. ↑ Pamela Kalte u. a .: American Men and Women of Science . Thomson Gale 2004.
2. ↑ release Intrexon retirement of Broder, 2016